lesnodynamics.blogg.se

If Authorized, Molnupiravir Could be the First Oral Antiviral Medicine for COVID-19

as Soon as Possible and to Submit Applications to Regulatory Agencies Worldwide Merck Plans to Seek Emergency Use Authorization in the U.S.

At the Interim Analysis, 7.3 Percent of Patients Who Received Molnupiravir Were Hospitalized Through Day 29, Compared With 14.1 Percent of Placebo-Treated Patients Who were Hospitalized or Died